Trace element levels: How Substance Use Disorder (SUD) contributes to the alteration of urinary essential and toxic element levels.

Increasing illicit drug use is one of the main problems in most countries or societies. Monitoring heavy metals and trace elements in this vulnerable group seems to be necessary. Therefore, we assessed the urinary trace element and toxic metals/metalloids concentrations (Zinc (Zn), Iron (Fe), Copper (Cu), Chromium (Cr), Lead (Pb), Cadmium (Cd), Arsenic (As), Nickel (Ni), and Mercury (Hg)) in opium, tramadol, and cannabis users compared to healthy subjects. In this cross-sectional study, patients with substance use disorder (SUD) (n = 74) were divided into four groups: cannabis, tramadol, opium, and mixed (simultaneous use of more than one of the three studied substances), along with a healthy group (n = 60). Urine samples were prepared by dispersive liquid-liquid microextraction method so that heavy metals/metalloids could be measured by ICP-MS. The mean urinary concentration of Cu (48.15 vs. 25.45; 89.2%, p<0.001), Hg (1.3 vs. 0.10; 1200%, p < 0.001), and Zn (301.95 vs. 210; 43.8%, p < 0.001) was markedly lower among patients with SUD. The mean urinary concentration of other elements including As (1.9 vs. 4.1; 115.8%), Cd (0.1 vs. 1.10; 1000%), Cr (6.80 vs. 11.65; 71.3%), Ni (2.95 vs. 4.95; 67.8%), and Pb (1.5 vs. 7.9; 426.6%) were significantly higher among patients with SUD compared to healthy subjects. When sub-groups were compared, no significant differences were observed between their trace element levels (Kruskal-Wallis test, p > 0.05). This can be an indication that regardless of the type of drug, the levels of trace elements are changed with respect to healthy individuals. Our results showed that illicit drug use causes changes in urinary trace element/heavy metal/metalloid levels and highlights the need for monitoring heavy metals and trace elements in individuals with substance use disorder. Assessment of different elements in biological samples of drug dependents may be useful for implementing new prevention and treatment protocols. In case of changes in their levels, complementary recommendations, attention to diet, and periodic assessment of toxic metal levels within treatment programs will be needed.

Separation of chromium(III) and chromium(VI) by ion chromatography and an inductively coupled plasma mass spectrometer as element-selective detector.

Due to its extensive use in industrial processes, large quantities of chromium compounds are discharged into the environment. Common approaches for the speciation of Cr employ the determination of Cr(VI) and total Cr. The focus of the present work was a separation of Cr(III) and Cr(VI) species, with a minimum of sample preparation, by keeping an eye on the more relevant and toxic Cr(VI). For the successful simultaneous separation of both chromium species we implemented a RSpak NN-814 4DP (PEEK, 4 mm x 150 mm) multi-mode column using an eluent containing 90 mM ammonium sulfate and 10 mM ammonium nitrate, adjusted to pH 3.5. At a flow of 0.3 mL min(-1) the separation of both Cr species was possible within 8 min. Further the octopole reaction system of the inductively coupled plasma mass spectrometer was systematically studied and optimised to reduce the influence of polyatomic interferences. The major advantage of the developed method compared to published methods is that a derivatisation of the Cr(III) species--an invasion in the speciation--is not required. With the used multi-mode column both chromium species are retained. Furthermore the pH of the mobile phase (pH 3.5) prevents reduction of Cr(VI) as well as precipitation of Cr(III) during the analysis. A limit of determination of approximately 0.5 microg L(-1) for both chromium species with an injection volume of 25 microL was obtained. The optimised method was successfully applied to the determination of Cr(VI) in cement samples as well as chromium speciation analysis in homeopathic drugs.